신경섬유종증 2형에서 표적치료: 임상시험의 현황

• 영문명: Targeted therapy on neurofibromatosis type 2: Current state of clinical trials
• 발행기관: 대한두개저학회
• 저자명: 전경화 이종대
• 간행물 정보: 『대한두개저학회지』제18권 제1호, 1~5쪽, 전체 5쪽
• 주제분류: 의약학 > 일반외과학
• 파일형태: PDF
• 발행일자: 2023.05.31

영문 초록

Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder characterized as bilateral vestibular schwannoma (VS), various brain and spinal tumors. Therapeutic options for NF2 patients have been limited to surgery and radiation. However, outcomes are not effective for NF2-related VSs. Understanding the molecular mechanisms driving NF2 pathogenesis holds promise for the potential use of targeted therapy. Many targeted therapies have been evaluated in preclinical models. Several clinical trials have been conducted to stop tumor growth and, in some cases, to improve cer-tain signs and symptoms of NF2, such as hearing loss. We review the current state of clinical trials of NF2.

목차

INTRODUCTION

DRUGS COMPLETING CLINICAL TRIALS (Table 2)

DRUGS ONGOING CLINICAL TRIALS (Table 3)

DRUG SCHEDULED FOR CLINICAL TRIALS

CONCLUSION

CONFLICT OF INTEREST

ORCID

REFERENCES

키워드

Vestibular schwannoma Molecular targeted therapy Clinical trial